Wiskott-Aldrich综合征患者的白细胞介素-1阻断治疗:一项回顾性多国病例系列研究
该多国回顾性病例系列分析了9例Wiskott-Aldrich综合征(WAS)患者接受抗IL-1药物(阿那白滞素或卡那单抗)治疗的情况,所有患者均有突出的炎症表现,糖皮质激素治疗部分或无应答,而抗IL-1治疗均迅速应答,常反应显著,使4例桥接至基因治疗、5例桥接至造血干细胞移植。
要点
- 9例WAS患者接受阿那白滞素或卡那单抗治疗,所有患者均有突出的炎症表现。
- 糖皮质激素治疗部分或无应答,抗IL-1治疗所有患者均迅速应答,常反应显著。
- 4例桥接至基因治疗,5例桥接至造血干细胞移植,治疗总体耐受良好。
核心结论
- WAS的部分炎症表现依赖IL-1,对抗IL-1药物阻断应答良好。
研究设计与样本
- 多中心回顾性分析,纳入9例接受抗IL-1药物(阿那白滞素或卡那单抗)治疗的WAS患者。
主要发现
- 所有患者均有突出的炎症表现,包括全身、皮肤、关节和肠道症状;3例自出生后最初数月即出现严重全身炎症综合征。
- 糖皮质激素治疗部分或无应答,而阿那白滞素或卡那单抗治疗所有患者均迅速应答,常反应显著。
- 4例桥接至基因治疗,5例桥接至造血干细胞移植;治疗总体耐受良好。
- 4例在造血干细胞移植后出现供者髓系嵌合率低,与炎症表现出现或复发相关。
- 2例接受第二次造血干细胞移植,达到完全供者嵌合和炎症表现缓解;另2例接受抗IL-1药物延长治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Up to 70% of patients with Wiskott-Aldrich syndrome (WAS) develop autoimmune and inflammatory manifestations. Dysregulation of interleukin 1 (IL-1) may be involved in their pathogenesis, yet there is little evidence on treatment with anti-IL-1 agents in these patients. We conducted a multicenter retrospective analysis of 9 patients with WAS treated with anti-IL-1 agents (anakinra or canakinumab). All patients had prominent inflammatory manifestations, including systemic, cutaneous, articular, and intestinal symptoms; 3 patients presented with a severe systemic inflammatory syndrome since the first months of life. Corticosteroid therapy was associated with partial or no response, whereas treatment with anakinra or canakinumab resulted in prompt, often dramatic, responses in all patients, allowing bridging to gene therapy (4 patients) or hematopoietic stem cell transplantation (HSCT; 5 patients). Treatment was overall well tolerated. Low donor myeloid chimerism developed in 4 patients after HSCT and was associated with the appearance or the recurrence of inflammatory manifestations. A second HSCT was performed in 2 patients, achieving full-donor chimerism and resolution of inflammatory manifestation, whereas the other 2 patients were treated with prolonged therapy with anti-IL-1 agents. Our experience demonstrates that some inflammatory manifestations of WAS are dependent on IL-1 and respond well to its pharmacologic blockade.
引用
- Naviglio S, Cicalese MP, Rivers E, et al. Interleukin-1 blockade in patients with Wiskott-Aldrich syndrome: a retrospective multinational case series. Blood. 2024. PMID: 39046813. doi:10.1182/blood.2024024524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。